1997
DOI: 10.1006/fsim.1997.0091
|View full text |Cite
|
Sign up to set email alerts
|

Adjuvant activity of polar glycopeptidolipids fromMycobacterium chelonaein experimental vaccines againstAeromonas salmonicidain salmonid fish

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
5
0

Year Published

2004
2004
2022
2022

Publication Types

Select...
6
2

Relationship

0
8

Authors

Journals

citations
Cited by 10 publications
(5 citation statements)
references
References 16 publications
0
5
0
Order By: Relevance
“…After transfer to seawater both temperature and growth increased and all groups showed increased levels of adhesions during summer and autumn in the sea. Other studies have also reported an increase in intra-abdominal lesions until 6 mo (Midtlyng et al 1996b, Mutoloki et al 2004) or more (Hoel & Lillehaug 1997) after vaccination. Others, e.g.…”
Section: Intra-abdominal Lesionsmentioning
confidence: 84%
See 2 more Smart Citations
“…After transfer to seawater both temperature and growth increased and all groups showed increased levels of adhesions during summer and autumn in the sea. Other studies have also reported an increase in intra-abdominal lesions until 6 mo (Midtlyng et al 1996b, Mutoloki et al 2004) or more (Hoel & Lillehaug 1997) after vaccination. Others, e.g.…”
Section: Intra-abdominal Lesionsmentioning
confidence: 84%
“…Hoel & Lillehaug (1997) found differences in weight between Atlantic salmon injected with an oil-adjuvanted vaccine and saline control, indicating that the vaccine itself makes a major contribution to the reduction in growth rate. Recently, Sørum & Damsgård (2004) found reduced feed intake and growth during the first 3 wk after vaccination, but anaesthetisation and handling alone had no significant effect on feed intake.…”
Section: Growth and Condition Factormentioning
confidence: 95%
See 1 more Smart Citation
“…Much attention has been focused on the effects of vaccination upon growth, feed intake and feed conversion efficiency [32][33][34][35][36][37][38][39] and on tissue lesions and intra-abdominal adhesions [32,34,35,40,41]. To date, no study has been performed on physiological stress response.…”
Section: Discussionmentioning
confidence: 99%
“…Type I facilitators represent substances that improve the persistence or uptake of antigen in tissues, such as the use of oil emulsions, delivered by intra-peritoneal (IP) injection, resulting in a slow release of the antigen into the peritoneal cavity and which boosts antigen presentation and immunity [7]. Type II facilitators refer to compounds that directly enhance the immune response of the host, such as aluminium hydroxide or bacterial toxins [7][8][9]. When added to the vaccine, these provide an enhanced stimulus, triggering superior antigen presentation and a heightened adaptive immune response.…”
Section: Introductionmentioning
confidence: 99%